Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Hansson L  
The Impact of Systolic Blood Pressure Control in Angiotensin II Antagonist Blockade

Journal of Clinical and Basic Cardiology 2001; 4 (2): 131-134

PDF    Summary    Figures   

Fig. 1: Sphygmomanometer Fig. 2: Eprosartan - Enalapril - Blutdruck Fig. 3: Eprosartan - Enalapril - Blutdruck

Keywords: Angiotensin-II-RezeptorblockadeEprosartankardiovaskuläre Morbiditätsystolische Hypertonieangiotensin II receptor blockadecardiovascular morbidityEprosartansystolic hypertension

Elevated systolic blood pressure is nowadays recognized as an even stronger predictor than elevated diastolic blood pressure of cardiovascular morbidity and mortality. Even borderline isolated systolic hypertension is associated with significant increases in cardiovascular risks. Moreover, large prospective intervention trials on the treatment of patients with isolated systolic hypertension have shown significant reductions in the risks of stroke and coronary heart disease. In this perspective it is of interest to note that the new angiotensin II receptor antagonist, the AT1 receptor selective agent eprosartan, has been shown to effectively reduce systolic blood pressure, both in patients with severe hypertension as well as in other patient groups.
copyright © 2003–2018 Krause & Pachernegg GmbH | Sitemap | Impressum